课题基金 / 基金详情

Epidemiology of Myelodysplastic Syndromes in Atomic Bomb Survivors

Epidemiology of Myelodysplastic Syndromes in Atomic Bomb Survivors
原子弹爆炸幸存者骨髓增生异常综合征的流行病学
批准号:
17590545
负责人:
IWANAGA Masako
金额:
$2.24万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2005
资助国家:
日本
项目状态:
已结题
起止时间:
2005 至 2006

项目摘要

项目成果

IWANAGA Masako的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
[Background] Myelodysplastic syndromes (MDS) are acquired clonal stem cell disorders characterized by ineffective hematopoiesis and a high risk of progression to leukemia. Etiologies of MDS are still unknown. So far, there is no large-scale epidemiological study for population exposed to radiation.[Aim] To investigate the association between radiation exposure and a risk of MDS in Atomic bomb survivors.[Methods] Overall MDS cases were retrospectively accumulated from five hospitals in Nagasaki City and then identified Atomic bomb survivors by linkage with the Database of Nagasaki Atomic Bomb Survivors in the Scientific Data Center at Nagasaki University. Disease confirmation was conducted with the microscopic examination of bone marrow smear and clinical data. In retrospective cohort analyses, we set a retrospective cohort of Atomic bomb survivors who were alive at 1980.1.1 but no MDS. In age-adjusted population analyses, we used official prefecture population statistics and then compared MDS incidence between Atomic bomb survivors and Non-Atomic bomb survivors.[Results] Up to now, we accumulated approximately 600 MDS cases diagnosed during 1970' to 2004, and identified around 200 cases who were Atomic bomb survivors. In retrospective cohort analyses, 162 MDS were identified among a cohort of 87496 survivors during 1980 to 2004 (crude incidence rate: 10.7 per 103 PY). Risk of MDS was high in male than female (RR=1.7), in survivors exposed within 1.5km from hypocenter than those over 3.0km (RR=4.3). Risk of subtypes of RAEB & RAEB-t was high compared with subtypes of RA & RARS among survivors exposed within 1.5km. In age-adjusted population analyses, crude incidence rate of MDS was higher in Atomic bomb survivors than Non-Atomic bomb survivors (crude incidence rate: 10.0 vs. 6.49 per 106 PY, RR=1.5).[Discussion] Results suggest a clear association between radiation exposure and a risk of MDS. Radiation dose analysis is needed to confirm this association.
期刊论文(26)
专著(0)
科研奖励(0)
会议论文
Epidemiology of MDS in Nagasaki City and Nagasaki A-bomb Survivors.
长崎市和长崎原子弹爆炸幸存者 MDS 的流行病学。
DOI: --
发表时间: 2006
期刊: Rinsho Ketsueki 47(9)
影响因子: --
作者: [Iwanaga M, et al.]
通讯作者: et al.
Epidemiology of MDS among Nagasaki Atomic Bomb Survivors.
长崎原子弹爆炸幸存者中 MDS 的流行病学。
DOI: --
发表时间: 2005
期刊: Leukemia Research 29・S1
影响因子: --
作者: [Masako Iwanaga, et al.]
通讯作者: et al.
特集 骨髄異形成症候群(MDS) : 病態の解明と最新の診療 MDS-診断と分類・鑑別すべき病態
专题:骨髓增生异常综合征(MDS):阐明病理学和最新治疗方法 MDS - 待诊断、分类和鉴别的病理状况
DOI: --
发表时间: 2006
期刊: 血液・腫瘍科 53・2
影响因子: --
作者: [Matsuo E, et al., 朝長万左男]
通讯作者: 朝長万左男
MDSの疫学研究 : 長崎市および長崎原爆被爆者集団における発生状況
长崎市及长崎原子弹爆炸幸存者人群MDS的流行病学研究
DOI: --
发表时间: 2006
期刊: 臨床血液 47・9
影响因子: --
作者: [Iwanaga M, et al., 岩永正子 他]
通讯作者: 岩永正子 他
19
    A new approach to elucidate the risk of malignant lymphoma in atomic bomb survivors
    • 批准号:
      16K15358
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $1.5万
    • 财政年份:
      2016
    • 负责人:
      IWANAGA Masako
    • 依托单位:
    Research on risk factors for the development of ATL: Long-term cohort study of HTLV-1-infected individuals.
    • 批准号:
      16H05248
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $10.48万
    • 财政年份:
      2016
    • 负责人:
      IWANAGA Masako
    • 依托单位:
    Risk evaluation based on the clinical characteristics of Hematological malignancies in atomic bomb survivors
    Risk assessment based on the clinical characteristics of leukemia and the related disorders in atomic bomb survivors
    • 批准号:
      20590649
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $3.0万
    • 财政年份:
      2008
    • 负责人:
      IWANAGA Masako
    • 依托单位:
    海外基金